Nanobiotix S.a. NBTX
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
Revenue compounded at +67.0% a year over the five years to FY2025.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
Return on equity has no reading this year — return on capital employed, just below, still does: -115%.
The 8-year record
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue €B | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income €B | −0.0 | −0.1 | −0.0 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 |
| EBITDA €B | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Income tax €B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income €B | −0.0 | −0.1 | −0.0 | −0.1 | −0.0 | −0.0 | −0.1 | −0.0 |
| Free cash flow €B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted € | −0.50 | −1.44 | −1.08 | −1.64 | −1.35 | −1.38 | −2.35 | −1.55 |
| Dividend / sh € | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — | — | — | — | — |
| ROE % | — | — | — | — | −96.8 | — | — | −213.1 |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
This company against its peers
Company facts, as filed
Reconciled in 8 of the 8 fiscal years we could check. 22 checks were skipped: the balance sheet is not tagged before 2018. 11 checks were skipped: EPS is not tagged before 2018.